ArticleJournal of clinical and experimental hepatology
Drug-induced Autoimmune-like Hepatitis With Pathological Features of Giant Cell Hepatitis.
Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Study of serum tumor markers in the early diagnosis of pancreatic cancer.World journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and methods: The differentiation between drug-induced autoimmune-like hepatitis (DI-ALH) and autoimmune hepatitis (AIH) can be confusing and challenging. We present a case of DI-ALH characterized by positive autoantibodies, elevated immunoglobulin G (IgG) levels and histology characteristics of giant cell hepatitis. Results: A liver biopsy was performed for etiology clarification, DI-ALH was diagnosed. Following treatment with corticosteroids and azathioprine, the patient's liver function remained normal without recurrence. Conclusions: Distinguishing DI-ALH from AIH based on the possibility of discontinuing immunosuppression and the histological features. Clinicians need to investigate patient's medical history, serological tests, and pathological changes to establish a correct diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.